Sign in
Active, not recruitingPhase 3

Efficacy Of Bovine Colostrum In The Treatment Of Severe Alcohol-Associated Hepatitis: A Randomized Controlled Trial

Key facts

Who runs it
Dayanand Medical College and Hospital
Where
India5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
174 people enrolled
Started
14 Nov 2017
Ended
Aug 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Bovine Colostrum
  • Placebo
Record updated
21 July 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Onset of jaundice within prior 8 weeks
  • Ongoing consumption of > 40 (female) or 60 (males) g alcohol/day for 6 months or more, with less than 60 days of abstinence before the onset of jaundice
  • Aspartate aminotransferase > 50, aspartate aminotransferase/alanine aminotransferase > 1.5, and both values < 400 IU/L
  • Serum bilirubin (total) > 3.0 mg/dL
  • Liver biopsy confirmation in patients with confounding factors including possible ischemic hepatitis (eg, severe upper gastrointestinal bleed, hypotension, or cocaine use within 7 days); possible DILI; uncertain alcohol use assessment (eg, patient denies excessive alcohol use); and atypical laboratory tests (eg, AST < 50 IU/mL or > 400 IU/mL, AST/ALT ratio < 1.5), antinuclear antibody > 1:160 or SMA > 1:80
  • Maddrey's discriminant function ≥ 32 assuming a control prothrombin time of 12 seconds
  • Model for End-stage Liver Disease score > 20

Who cannot take part

  • Uncontrolled drug addiction
  • Uncontrolled infections
  • Multiorgan failure
  • Uncontrolled upper gastrointestinal bleeding. "However, patients with recent Upper Gastro Intestinal bleeding, without significant hypotension that is controlled for >48 hours, will be included in the study."
  • Other underlying liver diseases including hepatitis B infection,* autoimmune liver diseases, Wilson disease, suspected drug-induced liver injury*
  • Hepatocellular carcinoma or other active malignancies except skin cancer
  • Cow milk allergy or severe lactose intol
  • Preexisting kidney injury with serum creatinine > 2.5 mg/dL
  • Pregnancy

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Severe alcohol-associated hepatitis (sAH)is associated with hepatocellular necrosis, inflammation, hyperactivated immune system, paradoxical immune exhaustion, leaky gut, and alteration in the gut microbiome. The leading cause of mortality is a bacterial infection with multi-organ failure.

Read full original descriptionShow less

Pentoxifylline was ineffective and Interleukin-1-based therapies - Anakinra and Canakinumab have not improved survival rates. The granulocyte colony-stimulating factor has shown mixed results. Indian studies improved 90-day survival, while Western studies on Pegfilgrastim have been negative. Corticosteroids decrease the mortality for only a month. In a recent study on Severe alcohol-associated hepatitis, Larsucosterol, a DNA methyltransferase inhibitor, was associated with non-significant improvement in 90-day mortality: 14.7 % (30 mg/day) and 16.67 % (90 mg/day) versus 24.27% on Methylprednisolone. Thus, a more durable treatment of severe alcohol-associated hepatitis is needed.

Bovine Colostrum contains many bioactive components such as immunoglobulin G, A, and M (70 - 80 % of total protein), Lactoferrin and Short-chain fatty acids. Bovine Colostrum has 30-100 times higher Lactoferrin concentration than milk. IgG and Lactoferrin synergistically neutralise lipopolysaccharide/ Endotoxin and act on mucosa-associated lymphoid tissue of the leaky gut, transforming it into healthy mucosa.

Fewer bacteria and Endotoxins - Pathogen-associated molecular patterns enter the portal circulation to interact with Toll-Like Receptor - 4 of the Liver Kupffer cells. Proinflammatory cytokines such as interleukins-1,6,8 and tumour necrosis factor-alpha, generation decreases, mitigating hepatocyte inflammation, necrosis, and cell death. We therefore conducted a multicenter, phase 3, double-blind, randomized, placebo-controlled trial to determine whether Bovine Colostrum, in addition to standard medical therapy, improves 90-day survival among patients with sAH. Secondary objectives were to assess its effects on liver disease severity, endotoxemia, systemic inflammatory markers, sepsis, and safety.

The 2 groups in the trial

  • Bovine colostrumTreatment being tested

    Protein 1.2 -1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a lyophilised freeze dried powder (20 gm thrice a day) for 4 weeks. \+ Antibiotics + Diuretics +Terlipressin along with IV Albumin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated

  • PlaceboPlacebo, for comparison

    Placebo (Pasteurized Milk Powder) 20 gms thrice a day for 4 weeks; isocaloric, isonitrogenous to the Bovine Colostrum, three times daily for 4 weeks, in addition to standard medical therapy and nutritional support. The placebo was formulated to match BC in appearance, consistency, and taste Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. \+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
21 July 2026